TY - JOUR
T1 - Combined Reporting of Surgical Quality and Cancer Control after Surgical Treatment for Penile Tumors with Inguinal Lymph Node Dissection :
T2 - The Tetrafecta Achievement
AU - Brassetti, Aldo
AU - Anceschi, Umberto
AU - Cozzi, Gabriele
AU - Chavarriaga, Julian
AU - Gavrilov, Pavel
AU - Gaya Sopena, Josep Maria
AU - Bove, Alfredo Maria
AU - Prata, Francesco
AU - Ferriero, Mariaconsiglia
AU - Mastroianni, Riccardo
AU - Misuraca, Leonardo
AU - Tuderti, Gabriele
AU - Torregiani, Giulia
AU - Covotta, Marco
AU - Camacho, Diego
AU - Musi, Gennaro
AU - Varela, Rodolfo
AU - Breda, Alberto
AU - De Cobelli, Ottavio
AU - Simone, Giuseppe
PY - 2023
Y1 - 2023
N2 - To optimize results reporting after penile cancer (PC) surgery, we proposed a Tetrafecta and assessed its ability to predict overall survival (OS) probabilities. A purpose-built multicenter, multi-national database was queried for stage I-IIIB PC, requiring inguinal lymphadenectomy (ILND), from 2015 onwards. Kaplan-Meier (KM) method assessed differences in OS between patients achieving Tetrafecta or not. Univariable and multivariable regression analyses identified its predictors. A total of 154 patients were included in the analysis. The 45 patients (29%) that achieved the Tetrafecta were younger (59 vs. 62 years; p = 0.01) and presented with fewer comorbidities (ASA score ≥ 3: 0% vs. 24%; p < 0.001). Although indicated, ILND was omitted in 8 cases (5%), while in 16, a modified template was properly used. Although median LNs yield was 17 (IQR: 11-27), 35% of the patients had <7 nodes retrieved from the groin. At Kaplan-Maier analysis, the Tetrafecta cohort displayed significantly higher OS probabilities (Log Rank = 0.01). Uni- and multivariable logistic regression analyses identified age as the only independent predictor of Tetrafecta achievement (OR: 0.97; 95%CI: 0.94-0.99; p = 0.04). Our Tetrafecta is the first combined outcome to comprehensively report results after PC surgery. It is widely applicable, based on standardized and reproducible variables and it predicts all-cause mortality.
AB - To optimize results reporting after penile cancer (PC) surgery, we proposed a Tetrafecta and assessed its ability to predict overall survival (OS) probabilities. A purpose-built multicenter, multi-national database was queried for stage I-IIIB PC, requiring inguinal lymphadenectomy (ILND), from 2015 onwards. Kaplan-Meier (KM) method assessed differences in OS between patients achieving Tetrafecta or not. Univariable and multivariable regression analyses identified its predictors. A total of 154 patients were included in the analysis. The 45 patients (29%) that achieved the Tetrafecta were younger (59 vs. 62 years; p = 0.01) and presented with fewer comorbidities (ASA score ≥ 3: 0% vs. 24%; p < 0.001). Although indicated, ILND was omitted in 8 cases (5%), while in 16, a modified template was properly used. Although median LNs yield was 17 (IQR: 11-27), 35% of the patients had <7 nodes retrieved from the groin. At Kaplan-Maier analysis, the Tetrafecta cohort displayed significantly higher OS probabilities (Log Rank = 0.01). Uni- and multivariable logistic regression analyses identified age as the only independent predictor of Tetrafecta achievement (OR: 0.97; 95%CI: 0.94-0.99; p = 0.04). Our Tetrafecta is the first combined outcome to comprehensively report results after PC surgery. It is widely applicable, based on standardized and reproducible variables and it predicts all-cause mortality.
KW - Tetrafecta
KW - Inguinal lymphadenectomy
KW - Penile cancer
KW - Surgical quality
KW - Survival
UR - https://www.scopus.com/pages/publications/85148739574
U2 - 10.3390/curroncol30020146
DO - 10.3390/curroncol30020146
M3 - Article
C2 - 36826107
SN - 1198-0052
VL - 30
SP - 1882
EP - 1892
JO - Current Oncology
JF - Current Oncology
IS - 2
ER -